PreciseDx Secures $20.7 Million Series B to Advance AI-Powered Cancer Risk Assessments | Healthcare IT Today
Funding will Support Expanded Commercialization Efforts for PreciseBreast Risk Assessment
PreciseDx, a leading innovator in oncology diagnostics leveraging Artificial Intelligence (AI) for new, morphology-driven disease analysis, today announced that it has raised $20.7 million in…
